A CDC7 inhibitor sensitizes DNA-damaging chemotherapies by suppressing homologous recombination repair to delay DNA damage recovery

Authors:

Abstract
Potential combination partners of a CDC7 inhibitor TAK-931 were identified to guide its clinical development strategy.
Funding Information
  • Takeda Science Foundation
  • the Grants-in-Aid for Scientific Research (20H03541)
  • The Grants-in-Aid for Fostering Joint International Research (20KK0187)
  • Takeda Pharmaceutical Company, Ltd

This publication has 45 references indexed in Scilit: